<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-147316</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Maintainance treatment of anti-neutrophil cytoplasm associated antibodies (ANCA)</dc:title>
<dc:description xml:lang="en">ANCA-associated vasculitides are rare and complex systemic diseases. Collaborative studies in both Europe and the United States of America have been particularly important in the development of randomized clinical trials that have studied the safety of maintenance therapy for these diseases. Although cyclophosphamide continues to be the main drug utilized during induction therapy, its long-term side effects have given rise to the study of other immunosuppressive drugs for the maintenance phase. We herein review these studies with particular attention to combination therapy and the duration of treatment (AU)</dc:description>
<dc:creator>Pedroza Granados, Jorge</dc:creator>
<dc:creator>Zúñiga Varga, Javier</dc:creator>
<dc:creator>Dábague Guzmán, Janet</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Las vasculitis asociadas a ANCA son enfermedades raras y complejas con compromiso sistémico. El desarrollo de grupos colaborativos en Europa y los Estados Unidos de América ha facilitado la realización de estudios clínicos aleatorizados para garantizar la seguridad en el tratamiento de mantenimiento de estas enfermedades. Aunque la ciclofosfamida continúa vigente para la fase de inducción, sus efectos adversos a largo plazo han propiciado el estudio de otras drogas inmunosupresoras en la fase demantenimiento. Aquí revisamos estos estudios con especial atención a los que se refieren a la combinación de medicamentos inmunosupresores y a la duración del tratamiento (AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);7(supl.3): s37-s40, dic. 2011. tab</dc:source>
<dc:identifier>ibc-147316</dc:identifier>
<dc:title xml:lang="es">Tratamiento de mantenimiento en las vasculitis asociadas a anticuerpos contra citoplasma de neutrófilos (ANCA)</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d53544^s22057</dc:subject>
<dc:subject>^d53544^s22016</dc:subject>
<dc:subject>^d54063^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30039^s22073</dc:subject>
<dc:subject>^d24852</dc:subject>
<dc:subject>^d6082^s22073</dc:subject>
<dc:subject>^d7724^s22073</dc:subject>
<dc:subject>^d4419</dc:subject>
<dc:subject>^d7344^s22020</dc:subject>
<dc:subject>^d3540^s22073</dc:subject>
<dc:subject>^d7344^s22073</dc:subject>
<dc:subject>^d38340</dc:subject>
<dc:subject>^d1394^s22073</dc:subject>
<dc:subject>^d3540^s22020</dc:subject>
<dc:subject>^d28169^s22073</dc:subject>
<dc:subject>^d54684</dc:subject>
<dc:subject>^d7344^s22000</dc:subject>
<dc:subject>^d54685</dc:subject>
<dc:subject>^d18001</dc:subject>
<dc:type>article</dc:type>
<dc:date>201112</dc:date>
</metadata>
</record>
</ibecs-document>
